eng Oriental Scientific Publishing Company Biomedical and Pharmacology Journal 0974-6242 2021-12-30 14 4 2319 2326 10.13005/bpj/2333 42191 article Fazeel Zubair Ahmed 1 Department of Pharmacology, Malla Reddy Medical College for Women, Hyderabad, India Background Potentiating activity of tablet apremilast 30mg BD against psoriasis in combination with 0.005% calcipotriol ointment was studied in comparison with calcipotriol monotherapy. Methods Single centre, prospective, parallel group, open label study compared efficacy and safety of calcipotriol+apremilast combination with calcipotriol monotherapy. Patients of mild to severe psoriasis in age group 18-60 years were randomized to two groups – calcipotriol+apremilast group and calcipotriol group. Calcipotriol+apremilast group received apremilast 30 mg BD p.o. and 0.005% calcipotriol ointment local application BD for 8 weeks. While calcipotriol group received 0.005% calcipotriol ointment local application BD for 8 weeks. Primary endpoint for efficacy was percentage of patients in whom mPASI decreased by 75% from baseline. Safety was also monitored throughout. Results 106 patients were randomized: calcipotriol+apremilast (n = 56) and calcipotriol group (n = 53). More patients of calcipotriol+apremilast achieved treatment success compared to calcipotriol was also higher (51.85% vs 34.61%; p < 0.001). Similar percentage of patients reported adverse events: Calcipotriol+apremilast 45.49% (n = 23) and calcipotriol 42.30% (n = 22) Conclusion Addition of apremilast to calcipotriol is significantly more efficacious than calcipotriol monotherapy. This combination is as safe as monotherapy. https://biomedpharmajournal.org/vol14no4/comparison-of-efficacy-and-safety-of-calcipotriol-and-apremilast-combination-against-cacipotriol-monotherapy-in-psoriasis/ Apremilast Calcipotriol  Corticosteroid  Psoriasis PDE4 Inhibitors Vitamin D